Etanercept

Generic Name: Etanercept

Brand Names: Enbrel, Eticovo, Benepali, Erelzi, Nepexto

Drug Type: Biotech

Chemical Formula: -

CAS Number: 185243-69-0

Unique Ingredient Identifier: OP401G7OJC

Background: Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. Etanercept is produced by recombinant DNA technolo...

Indication: Etanercept is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults and in chronic moderate to severe plaque psoriasis in patients 4 years of age and older. It is also used to manage signs and symptoms of polyarticular idiopathic arthritis and Juvenile Psoriatic Arthritis in those aged 2 years and older. Etanercept is al...

Associated Conditions: Active Juvenile Psoriatic Arthritis, Ankylosing Spondylitis (AS), Graft-versus-host Disease (GVHD), Polyarticular Juvenile Idiopathic Arthritis, Psoriasis Vulgaris (Plaque Psoriasis), Psoriatic Arthritis, Pyoderma Gangrenosum, Rheumatoid Arthritis, Severe Plaque psoriasis, Stevens-Johnson Syndrome, Chronic, severe Psoriatic Arthritis, Moderate Plaque psoriasis, Moderate, active Rheumatoid arthritis, Severe, active Rheumatoid arthritis

Associated Therapies: -

Clinical Trials

Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab

Phase 4

Terminated

Conditions: Psoriasis

Interventions: Drug: Etanercept

First Posted Date: 2012-03-02

Last Posted Date: 2017-12-29

Lead Sponsor: Amgen

Target Recruit Count: 64

Registration Number: NCT01543204

Locations: 🇨🇦
Research Site, Waterloo, Ontario, Canada

Extension Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis

Phase 3

Completed

Conditions: Juvenile Idiopahtic Arthritis

Interventions: Drug: etanercept

First Posted Date: 2011-08-22

Last Posted Date: 2022-11-14

Lead Sponsor: Pfizer

Target Recruit Count: 109

Registration Number: NCT01421069

Locations: 🇳🇴
Depart. of Rheumatology, Oslo, Norway
🇸🇮
University Medical Centre Ljubljana, University Children's Hospital, Ljubljana, Slovenia
🇮🇹
Centro di Ricerca Clinica - Fondazione dell'Universita' degli Studi "G. D'Annunzio", Chieti Scalo, Italy

and more 32 locations

Etanercept Treating Patient With Acute ST Segment Elevated Myocardial Infarction

Phase 4

Conditions: Myocardial Infarction

Interventions: Drug: saline
Drug: Etanercept

First Posted Date: 2011-06-14

Last Posted Date: 2011-06-14

Lead Sponsor: Xijing Hospital

Target Recruit Count: 200

Registration Number: NCT01372930

Locations: 🇨🇳
Xijing Hospital, Xi'an, Shaanxi, China

Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis

Phase 3

Completed

Conditions: Chronic Plaque Psoriasis

Interventions: Drug: Placebo
Drug: secukinumab (AIN457)
Drug: etanercept

First Posted Date: 2011-05-23

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1306

Registration Number: NCT01358578

Locations: 🇬🇧
Novartis Investigative Site, Nuneaton, United Kingdom

A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors

Phase 4

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Tocilizumab
Drug: Etanercept

First Posted Date: 2011-04-08

Last Posted Date: 2017-07-13

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 3080

Registration Number: NCT01331837

Locations: 🇺🇸
Emory Uni ; Division of Rheumatology, Atlanta, Georgia, United States
🇺🇸
Apex Medical Research, AMR, Inc., Chicago, Illinois, United States
🇺🇸
Columbus Arthritis Center, Columbus, Ohio, United States

and more 423 locations

Moderate Rheumatoid Arthritis (RA) With Etanercept (Enbrel)

Phase 4

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: etanercept
Drug: Placebo
Drug: DMARD Therapy

First Posted Date: 2011-03-11

Last Posted Date: 2017-02-09

Lead Sponsor: Amgen

Target Recruit Count: 210

Registration Number: NCT01313208

Locations: 🇨🇦
Research Site, Quebec, Canada

A Study to Evaluate the NSAIDS Sparing Effect of Etanercept in Subjects With Axial Spondyloarthritis

Phase 4

Completed

Conditions: Axial Spondyloarthritis

Interventions: Drug: etanercept
Drug: placebo

First Posted Date: 2011-02-17

Last Posted Date: 2014-07-29

Lead Sponsor: Pfizer

Target Recruit Count: 90

Registration Number: NCT01298531

Locations: 🇫🇷
Institut Calot - Fondation Hopale, Berck-sur-Mer, France
🇫🇷
Hopital Pellegrin, Bordeaux Cedex, France
🇫🇷
Centre Hospitalier, Service de Rhumatologie, Cahors, France

and more 16 locations